You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
Dermatology

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

Multidimensional disease burden of atopic dermatitis in children from a real-world case study – Presentation from the ADVENT symposium at EAACI 2023.

Peter  Arkwright
MD, PhD
Peter Arkwright

Learning objectives

  • Examine the multidimensional disease burden in children with AD and their families/caregivers, and the impact of type 2 comorbidities
  • Learn about the impact of targeting type 2 inflammation in children with AD, from the normalization of the skin barrier to the improvement of bone mineralization markers
  • Provide an overview of the treatment landscape in children with AD and examine updates on clinical trials of dupilumab

Description

In this ADVENT symposium at the 2023 EAACI congress, "Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention?”, Stephan Weidinger, MD, PhD (University Hospital Schleswig-Holstein), Peter Arkwright, MD, PhD (University of Manchester), and Oscar Palomares, PhD (University of Madrid) discussed the multidimensional disease burden of atopic dermatitis in children, the pathophysiology of the disease driven by type 2 inflammation, and the current treatment landscape for pediatric patients with atopic dermatitis.

MAT-GLB-2302884 V2 06/2023

About this expert

Allergy/Immunology

Peter Arkwright

MD, PhD

Senior Lecturer/Consultant in Paediatric Allergy and Immunology at the University of Manchester and Royal Manchester Children’s Hospital, UK

See author’s profile
Peter  Arkwright

Related resources